CELC vs. RNLX, XGN, DMTK, VCYT, CDNA, VRDN, CSTL, FLGT, SERA, and BDSX
Should you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Renalytix (RNLX), Exagen (XGN), DermTech (DMTK), Veracyte (VCYT), CareDx (CDNA), Viridian Therapeutics (VRDN), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Sera Prognostics (SERA), and Biodesix (BDSX). These companies are all part of the "medical laboratories" industry.
Celcuity (NASDAQ:CELC) and Renalytix (NASDAQ:RNLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
63.3% of Celcuity shares are held by institutional investors. Comparatively, 9.9% of Renalytix shares are held by institutional investors. 20.3% of Celcuity shares are held by company insiders. Comparatively, 17.8% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Celcuity has a net margin of 0.00% compared to Renalytix's net margin of -1,687.80%. Celcuity's return on equity of -61.66% beat Renalytix's return on equity.
Celcuity has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500.
Celcuity received 319 more outperform votes than Renalytix when rated by MarketBeat users. Likewise, 66.87% of users gave Celcuity an outperform vote while only 32.00% of users gave Renalytix an outperform vote.
Celcuity currently has a consensus target price of $29.50, suggesting a potential upside of 94.59%. Renalytix has a consensus target price of $5.00, suggesting a potential upside of 1,062.52%. Given Renalytix's higher possible upside, analysts plainly believe Renalytix is more favorable than Celcuity.
Renalytix has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Celcuity and Celcuity both had 3 articles in the media. Celcuity's average media sentiment score of 1.43 beat Renalytix's score of 1.19 indicating that Celcuity is being referred to more favorably in the media.
Summary
Celcuity beats Renalytix on 9 of the 15 factors compared between the two stocks.
Get Celcuity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celcuity Competitors List
Related Companies and Tools
